# Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

> **NCT01954589** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Safety
- Tolerability
- Pharmacodynamics
- Pharmacokinetics

## Interventions

- **DRUG:** ACT-462206 5 mg
- **DRUG:** ACT-462206 25 mg
- **DRUG:** ACT-462206 100mg
- **DRUG:** ACT-462206 200mg
- **DRUG:** ACT-462206 400mg
- **DRUG:** ACT-462206 1000 mg
- **DRUG:** ACT-462206 1500mg
- **DRUG:** Almorexant 400mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01954589
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2018-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954589, "Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01954589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*